SEC For	m 4																			
FORM 4 UNITED) STA	STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												OMB APPROVAL			
Section 16. Form 4 or Form 5 obligations may continue. See				ed pursu	NT OF CHANGES IN BENEFICIAL OWNERSHIP d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940											OMB Number: 3235-0287 Estimated average burden hours per response: 0.5				
1. Name and Address of Reporting Person [*] Altschuler Steven															5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last)	(F	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/14/2023									Officer (give title Other (specify below) below)							
C/O ORCHARD THERAPEUTICS PLC 245 HAMMERSMITH ROAD					4. lf /									. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person						
(Street) LONDON X0			W6 8PW		Person										led by More than One Reporting					
(City) (State)			(Zip)	Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																
		Tal	ole I - Non	-Deriv	ative	Se	curities	s Ac	quired, D	ispo	osed o	of, or Be	eneficial	y Owned						
1. Title of Security (Instr. 3)			2. Trans Date (Month)		saction /Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Ins	on		rities Acquired (A) or ed Of (D) (Instr. 3, 4 and		Beneficia Owned F	es ally Following	Form (D) o	: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) (D)	or Price	Reported Transact (Instr. 3 a	ion(s)			Instr. 4)			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/	ate, Ti C	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amouni of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				c	ode	v	(A)	(D)	Date Exercisable	Exp Date	oiration e	Title	Amount or Number of Shares	nt (In er						
Stock Option (Right to Buy)	\$0.495	06/14/2023			A		105,000		(1)	06/1	13/2033	Ordinary Shares ⁽²⁾	105,000	\$0.00	105,00	00	D			

Explanation of Responses:

1. All of the shares subject to this option vest upon the earlier to occur of June 14, 2024 or the date of the 2024 Annual General Meeting of the Company.

2. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents ten Ordinary Shares.

Remarks:

<u>/s/ Frank Thomas, as attorney-</u> <u>in-fact</u>

06/16/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.